Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD trial
. Diabetes Care. 2014;37(3):634-643.
Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Byington RP, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes
. N Engl J Med. 2011;364(9):818-828.
Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial
. Diabetes Care. 2010;33(5):983-990.
Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus
. N Engl J Med. 2010;362(17):1575-1585.
Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Goff DC Jr, Byington RP, et al. Effects of combination lipid therapy in type 2 diabetes mellitus
. N Engl J Med. 2010;362(17):1563-1574.
Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
. BMJ. 2010;340():b4909.
Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Espeland MA, et al. Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials
. Clin Trials. 2009;6(5):416-429.
Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes
. Diabetologia. 2009;52(11):2288-2298.
Furberg C, Byington R, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis
. Lancet. 2008;371(9607):117-125.
Agodoa L, Anderson C, Chalmers J, MacMahon S, Neal B, Asselbergs FW, van Gilst WH, Baigent C, Byington R, Turnbull F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials
. BMJ. 2008;336(7653):1121-1123.
Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods
. Am J Cardiol. 2007;99(12 Suppl 1):S21-S33.
Byington RP, Genuth S, Friedewald WT, Simons-Morton DG. Introduction
. Am J Cardiol. 2007;99(12 Suppl 1):1-3.
Agodoa L, Anderson C, Asseibergs F, Baigent C, Black H, Brenner B, Brown M, Bulpitt C, Byington R, Turnbull F, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system
. J Hypertens. 2007;25(7):951-958.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.